1. Market Snapshot: A Bumpy Ride for “Vape King”
In October, Hong Kong’s equities saw volatile sector rotation, especially between consumer electronics and healthcare. Yet Smoore International (06969.HK) — once hailed as the flagship vape stock — remains stuck in a prolonged bottoming process. As of intraday October 10, its share price stood at HKD 15.3, a drop of over 30% from its 2025 high of HKD 23.92.
The market’s ambivalence toward Smoore stems from two intertwined challenges: tightening global regulation on vaping and the uncertainty around its transition into new lines of business.
2. Near-Term Profit Pressure
2.1 UBS / Analyst Views: Revenue Growth but Eroding Margins
UBS recently reiterated a “Sell” rating on Smoore, setting a target price at HKD 13.11, implying further downside risk. Their research suggests that while 2025 revenue may grow ~20% (driven largely by vape sales), net profit could fall ~40% year-on-year, due to higher R&D and marketing costs plus margin compression.
In fact, UBS’s 2025–2027 net profit forecasts sit well below consensus—underscoring market concerns about Smoore’s ability to manage costs and maintain profitability under competitive pressure.
2.2 The Margin Squeeze: From “Grow Fast” to “Grow Smart”
Historically, vape manufacturers have enjoyed a favorable pricing environment. But as regulations tighten globally, brands and OEMs increasingly compete on cost efficiency. For Smoore, this means:
- Tightened bargaining power with clients (who push for cost cuts)
- Rising raw material and component costs
- Escalating overheads in compliance, safety, and R&D
These pressures are already visible: R&D expense ratio rose from ~4 % to 8.3 % (2020 → 2023), while sales & marketing costs climbed from 3.2 % to 5.1 %. These “future investments” are necessary but exert near-term drag on profitability.
3. Long-Term Pivot: Medical Inhalation as a Growth Lever
3.1 FDA Acceptance Marks a Milestone
Amid skepticism on its core business, Smoore’s most compelling narrative lies in the medical inhalation vertical. On September 23, its wholly-owned subsidiary Transpire Bio (or “ChuanSi Biotech”) announced that its ANDA (abbreviated new drug application) for a generic version of Breo® Ellipta® had been officially accepted by the U.S. FDA.
Notably, Transpire claims to be first to file under “Paragraph IV certification” in the context of the Hatch-Waxman Act—positioning it for 180 days of market exclusivity if the generic is approved.
Breo Ellipta is a blockbuster inhaled therapy for asthma and COPD. In 2024, it recorded U.S. sales of approximately USD 2.02 billion.
3.2 Challenges in Medical Commercialization
Although FDA acceptance is a landmark, it’s just the beginning. Key risks remain:
- The timeline from acceptance → approval → commercialization often takes 1–2 years
- Must pass bioequivalence, manufacturing, and device–drug integration tests
- Potential patent litigation from the original R&D company
- High upfront capex and operating costs before material revenue contribution
Even if approved, the medical business likely will not meaningfully offset near-term weakness in vaping revenues.
Additionally, Transpire has already taken a step further by signing an agreement with Recipharm to co-develop inhaled medicines TRB-1 and TRB-2 for asthma/COPD treatment.
4. Financials & Recent Trends
- In Q3 2025, Smoore reported revenue of RMB 4,196.8 million, up 27.2 % YoY.
- Over the first nine months, revenue totaled ~RMB 10.21 billion, up 21.8 % YoY.
- Yet, despite revenue growth, pre-tax profit declined ~15 % over the same period.
- The adjusted profit rose modestly (~4 %) in Q3 2025, aided by scale effects and expense control.
5. Why the Stock Remains Under Pressure
Smoore’s share price languishing near the bottom reflects market skepticism toward two core concerns:
- Near-term earnings contraction — even with revenue growth, the drag from rising margins and investments is real.
- Unclear path for new verticals — while medical inhalation holds promise, it is nascent and not yet proven as a value driver.
In short: the market is asking, can Smoore bridge from a high-growth vaping model to a medically diversified, value-generating enterprise?
6. Outlook & What to Watch
| Catalyst / Risk | Potential Impact | Timeline |
|---|---|---|
| Cost control & margin rebound in vaping | Could boost near-term profitability | 2025 |
| FDA’s final decision on ANDA | Key inflection point for medical business | 2026 |
| Patent disputes / litigation risk | Could delay or block commercialization | 2025–2027 |
| Scale in new inhalation drug pipelines | Long-term value driver | 2027+ |
| Regulatory tightening or relaxation globally | Volume and margin swing risk | Ongoing |
To support investor confidence, Smoore needs to demonstrate execution in cost optimization, commercial traction in inhalation medicine, and clarity in its strategic timeline.